ArticleScience advances2022
Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 117 citations in OpenAlex.
- Supramolecular Zinc-Polyphenol Coordination Assemblies Mitigate Colonic Inflammation by Regulating Mucosal Barrier and Microbiome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Natural carrier-free self-assembled binary polyphenol nanoparticles remodel the gut microenvironment for inflammatory bowel disease prevention.Materials today. Bio · 2026Article
- Carrier-free supramolecular architectonics of quercetinMaterials today. Bio · 2026Article
- Targeted intestinal barrier repairActa pharmaceutica Sinica. B · 2026Article
- Oral colon targeted curcumin-based nanocomposite inulin hydrogel for alleviating intestinal inflammation and dysbiosis.Journal of nanobiotechnology · 2026Article
- Male germ cell-specific deletion ofZoological research · 2026Article
- Novel triterpenoids from Ganoderma resinaceum attenuate UV-induced photoaging via modulating Nrf2 and MAPK signaling pathways.Natural products and bioprospecting · 2026Article
- Shenfu Decoction Extends Survival Time of Seawater-Induced Hypothermia in Rats: The Role of Metabolomics and Gut Microbiota.Current drug metabolism · 2026Article
- Biomimetic Layered Double Hydroxide-Molybdenum Disulfide Encapsulated with Bovine Serum Albumin: A Multifaceted Nanotherapy for Inflammatory Bowel Disease.Biomaterials research · 2026Article
- Reactive oxygen species/hypoxia dual-responsive polymers combined with melatonin inhibited PANoptosis of retinal ganglion cells for acute glaucoma treatment.Theranostics · 2026Article
- Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis.Nature communications · 2025Article
- Regulation of hydrogen and oxidative stress in treating intestinal mucosa from ulcerative colitis.International journal of pharmaceutics: X · 2025Article
- DNAzyme targeting RIP3 suppresses NLRP3-mediated necroinflammation for the treatment of inflammatory diseases.Acta pharmaceutica Sinica. B · 2025Article
- Engineered probiotic alleviates ulcerative colitis by inhibiting M1 macrophage polarization via glycolytic reprogramming.Bioengineering & translational medicine · 2025Article
- Spontaneous hydrogen-releasing nanoenzyme alleviates osteoarthritis via oxidative stress reduction and mitochondrial dysfunction reversal.Journal of nanobiotechnology · 2025Article
- Progress and challenges of functionalized bacterial encapsulation: A novel biotechnology for next-generation biotherapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Antibody-functionalized iron-based nanoplatform for ferroptosis-augmented targeted therapy of HER2-positive breast cancer.Bioactive materials · 2025Article
- Pathogenesis guided application of nanozymes in the treatment of inflammatory bowel disease.Materials today. Bio · 2025Review
- Molybdenum facilitates PDLSC-based bone regeneration through the JAK/STAT3 signaling pathway.Scientific reports · 2025Article
- A cerium nanocluster for effective alleviation of inflammatory bowel disease by scavenging RONS and regulating gut microbiome.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) affects millions of people each year. The overproduction of reactive oxygen species (ROS) plays a critical role in the progress of IBD and will be a potential therapeutic target. Here, we synthesize a kind of oral zero-valent-molybdenum nanodots (ZVMNs) for the treatment of IBD by scavenging ROS. These ultrasmall ZVMNs can successfully pass through the gastric acid and then be absorbed by the intestine. It has been verified that ZVMNs can down-regulate the quantity of ROS and reduce colitis in a mouse IBD model without distinct side effects. In addition, RNA sequencing reveals a further mechanism that the ZVMNs can protect colon tissues from oxidative stress by inhibiting the nuclear factor κB signaling pathway and reducing the production of excessive pro-inflammatory factors. Together, the ZVMNs will offer a promising alternative treatment option for patients suffering from IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.